Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

<h4>Background</h4> <p>In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. U...

Full description

Bibliographic Details
Main Authors: Chi, K, Protheroe, A, Rodríguez-Antolín, A, Facchini, G, Suttman, H, Matsubara, N, Ye, Z, Keam, B, Damião, R, Li, T, McQuarrie, K, Jia, B, De Porre, P, Martin, J, Todd, M, Fizazi, K
Format: Journal article
Language:English
Published: Elsevier 2018

Similar Items